Michael J Evans

List of Publications by Year
in descending order

66 papers	2,506 citations	236925 25 h-index	206112 48 g-index
71 all docs	71 docs citations	71 times ranked	4479 citing authors

#	Article	IF	Citations
1	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9578-9582.	7.1	268
2	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	5.9	167
3	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	5.0	166
4	Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 2018, 10, .	12.4	124
5	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	6.4	116
6	Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chemistry, 2018, 29, 96-103.	3.6	109
7	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.9	105
8	Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. Journal of Clinical Investigation, 2018, 129, 349-363.	8.2	99
9	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	2.2	86
10	Annotating MYC status with 89Zr-transferrin imaging. Nature Medicine, 2012, 18, 1586-1591.	30.7	83
11	Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals. Inorganic Chemistry, 2014, 53, 1880-1899.	4.0	75
12	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology, 2018, 1, 78-82.	5.4	74
13	Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. ELife, 2018, 7, .	6.0	72
14	Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology. Journal of Nuclear Medicine, 2013, 54, 1876-1882.	5.0	58
15	Junctional Adhesion Mechanisms in Airway Basal Cells. American Journal of Respiratory Cell and Molecular Biology, 1990, 3, 341-347.	2.9	38
16	Caged [¹⁸F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjugate Chemistry, 2016, 27, 170-178.	3.6	38
17	Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Central Science, 2019, 5, 727-736.	11.3	38
18	A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4. Bioconjugate Chemistry, 2018, 29, 3476-3482.	3.6	37

#	Article	IF	Citations
19	Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Molecular Pharmaceutics, 2019, 16, 3831-3841.	4.6	36
20	Fibroblast growth factor-2 during postnatal development of the tracheal basement membrane zone. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L1263-L1270.	2.9	34
21	Fibroblast Growth Factor-2 in Remodeling of the Developing Basement Membrane Zone in the Trachea of Infant Rhesus Monkeys Sensitized and Challenged with Allergen. Laboratory Investigation, 2002, 82, 1747-1754.	3.7	33
22	Imaging Tumor Burden in the Brain with ⁸⁹Zr-Transferrin. Journal of Nuclear Medicine, 2013, 54, 90-95.	5.0	33
23	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 946-951.	2.6	33
24	Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clinical Cancer Research, 2017, 23, 3045-3052.	7.0	31
25	Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with ¹⁸F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 51-57.	5.0	31
26	In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Central Science, 2021, 7, 1638-1649.	11.3	30
27	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	5.9	29
28	Three-Dimensional Organization of the Lamina Reticularis in the Rat Tracheal Basement Membrane Zone. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 393-397.	2.9	27
29	A reactivity-based [¹⁸F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chemical Science, 2016, 7, 5503-5507.	7.4	27
30	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	3.4	27
31	Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight, 2018, 3, .	5.0	26
32	Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET. Journal of Nuclear Medicine, 2014, 55, 2045-2049.	5.0	25
33	Synthesis and Characterization of ⁸⁹Zr-Labeled Ultrasmall Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2596-2601.	4.6	24
34	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3608-3615.	7.0	24
35	Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. Journal of Nuclear Medicine, 2021, 62, jnumed.120.252460.	5.0	21
36	Site-Specific Radiofluorination of Biomolecules with 8-[¹⁸F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chemical Biology, 2016, 11, 1587-1594.	3.4	18

#	Article	IF	Citations
37	Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clinical Cancer Research, 2021, 27, 1305-1315.	7.0	18
38	Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer. Cancer Discovery, 2012, 2, 985-994.	9.4	16
39	Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Molecular Imaging and Biology, 2020, 22, 208-216.	2.6	16
40	Ferrous ironâ€“activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. Journal of Experimental Medicine, 2022, 219, .	8.5	15
41	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 166-176.	7.0	14
42	Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. Journal of Clinical Investigation, 2022, 132, .	8.2	13
43	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	1.9	12
44	Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Molecular Pharmaceutics, 2016, 13, 683-688.	4.6	12
45	Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chemical Biology, 2017, 12, 2934-2939.	3.4	11
46	An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Molecular Imaging and Biology, 2020, 22, 1553-1561.	2.6	11
47	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats. Journal of Nuclear Medicine, 2022, 63, 1259-1265.	5.0	11
48	Epidemiology and treatment of BehÃ§etâ€™s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Research and Therapy, 2021, 23, 224.	3.5	10
49	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	7.0	10
50	Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. ACS Applied Materials & Interfaces, 2021, 13, 54739-54752.	8.0	9
51	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. International Journal of Radiation Oncology Biology Physics, 2020, 108, 242-257.	0.8	8
52	Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Molecular and Cellular Proteomics, 2020, 19, 294-307.	3.8	8
53	Measuring glucocorticoid receptor expressionin vivowith PET. Oncotarget, 2018, 9, 20399-20408.	1.8	8
54	Switchable assembly and function of antibody complexes inÂvivo using a small molecule. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7

#	Article	IF	Citations
55	Imaging Hepatocellular Carcinoma With⁶⁸Ga-Citrate PET: First Clinical Experience. Molecular Imaging, 2017, 16, 153601211772325.	1.4	6
56	Arabinofuranoseâ€derived positronâ€emission tomography radiotracers for detection of pathogenic microorganisms. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 231-239.	1.0	5
57	Synthesis and Screening of Î±-Xylosides in Human Glioblastoma Cells. Molecular Pharmaceutics, 2021, 18, 451-460.	4.6	5
58	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4
59	A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chemical Biology, 2020, 15, 1381-1391.	3.4	4
60	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatologyâ€™s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
61	The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (Â±)-¹¹C-YJH08 PET. Journal of Nuclear Medicine, 2021, 62, 723-731.	5.0	2
62	In Vivo Profiling with ¹⁸F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Molecular Pharmaceutics, 2022, 19, 704-709.	4.6	2
63	The Basement Membrane Zone in Asthma: The Supracellular Anchoring Network. Current Respiratory Medicine Reviews, 2014, 9, 268-273.	0.2	0
64	Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods in Molecular Biology, 2019, 2033, 191-205.	0.9	0
65	Exploiting KRAS-Driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC). SSRN Electronic Journal, 0, , .	0.4	0
66	Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods in Molecular Biology, 2022, 2393, 829-839.	0.9	0